{"title":"年龄和合并症对在印度尼西亚国家转诊医院接受瑞德西韦治疗的确诊临床危重型COVID-19患者预后的影响","authors":"Usman Elly, Katar Yusticia","doi":"10.21010/Ajidv17i1.5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is currently no viable pharmaceutical therapy for COVID-19 illness that has been validated. The use of remdesivir is one of the medications for which there is no consistent evidence of a significant therapeutic benefit or a meaningful effect on survival.</p><p><strong>Aim: </strong>The aim of this study was to determine the role of age and comorbidities on the outcome of confirmed clinically critical COVID-19 patients treated with remdesivir at Indonesia's National Referral Hospital.</p><p><strong>Methods: </strong>A retrospective cohort study was used in this study. The subjects in this study were confirmed clinically critical COVID-19 patients who were treated at Dr. M Djamil Hospital Padang, one of Indonesia's national referral hospitals, from January 2 to June 30, 2021. The number of sample size in this study was 90 patients. The variables of this study were divided into three independent variables (age, comorbidities, and a number of comorbidities). A dependent variable was the outcome of confirmed clinically critical COVID-19 patients. The Chi-square test was performed in bivariate analysis, and the odds ratio was calculated. SPSS version 17.0 was used to analyze the data.</p><p><strong>Results: </strong>The results of this study found that there was an association between ages 50-59 years (OR = 10.23, 95% CI 1.89-55.53), 60-69 years (OR = 4.58, 95% CI 1.25-16.76), and > 70 years (OR = 1.91, 95% CI 1.38 -9.59), comorbid diabetes mellitus (OR = 9.78, 95% CI 1.23-77.66), the number of comorbid > 1 (OR = 10.97, 95% CI 2.19-54.96, and the number of comorbid 1 (OR = 5.69, 95% CI 1.59- 20.41) with the outcome of confirmed clinically critical COVID-19 patients treated with remdesivir.</p><p><strong>Conclusion: </strong>The significance of age and comorbidities on the outcome of COVID-19 patients treated with remdesivir at Indonesia's national referral hospital was confirmed in this study. This study could assist in the management of patient therapy, potentially decreasing morbidity and even patient mortality.</p>","PeriodicalId":39108,"journal":{"name":"African Journal of Infectious Diseases","volume":"17 1","pages":"55-59"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885022/pdf/","citationCount":"0","resultStr":"{\"title\":\"THE ROLE OF AGE AND COMORBIDITIES ON THE OUTCOME OF CONFIRMED CLINICALLY CRITICAL COVID-19 PATIENTS TREATED WITH REMDESIVIR AT INDONESIA'S NATIONAL REFERRAL HOSPITAL.\",\"authors\":\"Usman Elly, Katar Yusticia\",\"doi\":\"10.21010/Ajidv17i1.5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>There is currently no viable pharmaceutical therapy for COVID-19 illness that has been validated. The use of remdesivir is one of the medications for which there is no consistent evidence of a significant therapeutic benefit or a meaningful effect on survival.</p><p><strong>Aim: </strong>The aim of this study was to determine the role of age and comorbidities on the outcome of confirmed clinically critical COVID-19 patients treated with remdesivir at Indonesia's National Referral Hospital.</p><p><strong>Methods: </strong>A retrospective cohort study was used in this study. The subjects in this study were confirmed clinically critical COVID-19 patients who were treated at Dr. M Djamil Hospital Padang, one of Indonesia's national referral hospitals, from January 2 to June 30, 2021. The number of sample size in this study was 90 patients. The variables of this study were divided into three independent variables (age, comorbidities, and a number of comorbidities). A dependent variable was the outcome of confirmed clinically critical COVID-19 patients. The Chi-square test was performed in bivariate analysis, and the odds ratio was calculated. SPSS version 17.0 was used to analyze the data.</p><p><strong>Results: </strong>The results of this study found that there was an association between ages 50-59 years (OR = 10.23, 95% CI 1.89-55.53), 60-69 years (OR = 4.58, 95% CI 1.25-16.76), and > 70 years (OR = 1.91, 95% CI 1.38 -9.59), comorbid diabetes mellitus (OR = 9.78, 95% CI 1.23-77.66), the number of comorbid > 1 (OR = 10.97, 95% CI 2.19-54.96, and the number of comorbid 1 (OR = 5.69, 95% CI 1.59- 20.41) with the outcome of confirmed clinically critical COVID-19 patients treated with remdesivir.</p><p><strong>Conclusion: </strong>The significance of age and comorbidities on the outcome of COVID-19 patients treated with remdesivir at Indonesia's national referral hospital was confirmed in this study. This study could assist in the management of patient therapy, potentially decreasing morbidity and even patient mortality.</p>\",\"PeriodicalId\":39108,\"journal\":{\"name\":\"African Journal of Infectious Diseases\",\"volume\":\"17 1\",\"pages\":\"55-59\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885022/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"African Journal of Infectious Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21010/Ajidv17i1.5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"African Journal of Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21010/Ajidv17i1.5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
背景:目前还没有针对COVID-19疾病的可行药物治疗方法得到验证。瑞德西韦的使用是一种没有一致证据表明有显著治疗益处或对生存有意义影响的药物。目的:本研究的目的是确定年龄和合并症对印度尼西亚国家转诊医院接受瑞德西韦治疗的确诊临床危重型COVID-19患者预后的作用。方法:采用回顾性队列研究。本研究的受试者为2021年1月2日至6月30日在印度尼西亚国家转诊医院巴东M博士医院治疗的临床危重患者。本研究样本量为90例。本研究的变量分为三个独立变量(年龄、合并症和一些合并症)。一个因变量是确诊的临床危重患者的预后。双因素分析采用卡方检验，计算优势比。采用SPSS 17.0版本对数据进行分析。结果:这项研究的结果发现,有一个协会50年龄59岁之间(或= 10.23,95% CI 1.89 - -55.53), 60 - 69岁(或= 4.58,95% CI 1.25 - -16.76), > 70年(或= 1.91,95% CI 1.38 - -9.59),并发糖尿病(或= 9.78,95% CI 1.23 - -77.66),共病的数量> 1(或= 10.97,95% CI 2.19 - -54.96,共病的数量1(或= 5.69,95%可信区间1.59 - 20.41)的结果证实临床remdesivir患者COVID-19至关重要。结论:本研究证实了年龄和合并症对印度尼西亚国家转诊医院新冠肺炎患者瑞德西韦治疗结果的重要意义。这项研究可以帮助患者治疗管理，潜在地降低发病率甚至患者死亡率。
THE ROLE OF AGE AND COMORBIDITIES ON THE OUTCOME OF CONFIRMED CLINICALLY CRITICAL COVID-19 PATIENTS TREATED WITH REMDESIVIR AT INDONESIA'S NATIONAL REFERRAL HOSPITAL.
Background: There is currently no viable pharmaceutical therapy for COVID-19 illness that has been validated. The use of remdesivir is one of the medications for which there is no consistent evidence of a significant therapeutic benefit or a meaningful effect on survival.
Aim: The aim of this study was to determine the role of age and comorbidities on the outcome of confirmed clinically critical COVID-19 patients treated with remdesivir at Indonesia's National Referral Hospital.
Methods: A retrospective cohort study was used in this study. The subjects in this study were confirmed clinically critical COVID-19 patients who were treated at Dr. M Djamil Hospital Padang, one of Indonesia's national referral hospitals, from January 2 to June 30, 2021. The number of sample size in this study was 90 patients. The variables of this study were divided into three independent variables (age, comorbidities, and a number of comorbidities). A dependent variable was the outcome of confirmed clinically critical COVID-19 patients. The Chi-square test was performed in bivariate analysis, and the odds ratio was calculated. SPSS version 17.0 was used to analyze the data.
Results: The results of this study found that there was an association between ages 50-59 years (OR = 10.23, 95% CI 1.89-55.53), 60-69 years (OR = 4.58, 95% CI 1.25-16.76), and > 70 years (OR = 1.91, 95% CI 1.38 -9.59), comorbid diabetes mellitus (OR = 9.78, 95% CI 1.23-77.66), the number of comorbid > 1 (OR = 10.97, 95% CI 2.19-54.96, and the number of comorbid 1 (OR = 5.69, 95% CI 1.59- 20.41) with the outcome of confirmed clinically critical COVID-19 patients treated with remdesivir.
Conclusion: The significance of age and comorbidities on the outcome of COVID-19 patients treated with remdesivir at Indonesia's national referral hospital was confirmed in this study. This study could assist in the management of patient therapy, potentially decreasing morbidity and even patient mortality.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
